Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NANT CRC Vaccine vs Regorafenib in metastatic CRC
NCT03563157Phase 2Terminated
- Sponsor
- ImmunityBio, Inc.
- Start
- Sep 2018
- Primary completion
- Apr 2019
- Modality
- Adenoviral Vectors, DNA Vaccines, Peptide-based Cancer Vaccines
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of nogapendekin alfa inbakicept, haNK, aldoxorubicin, ETBX-011, ETBX-021 and 5 more in colorectal cancer (metastatic) (mCRC) (2 arms), sponsored by ImmunityBio, Inc. Primary endpoint: Treatment-emergent Adverse Events up to 6 months. Started Sep 2018; status: terminated.
02
Drugs
nogapendekin alfa inbakicepthaNKaldoxorubicinETBX-011ETBX-021
03
Conditions
colorectal cancer (metastatic) (mCRC)
Beyond the preview
Go deeper on NCT03563157.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03563157.